Stock Performance and Market Context
On 16 Mar 2026, Link Pharma Chem Ltd’s shares declined sharply by 11.01% intraday, hitting the new low of Rs.22.31. This drop extended a losing streak spanning four consecutive sessions, during which the stock has fallen by 20.32%. The day’s trading was marked by high volatility, with an intraday volatility of 6.65% based on the weighted average price. The stock’s performance lagged its sector by 9.9% on the day, underscoring its relative weakness within the Commodity Chemicals industry.
Technically, the stock is trading below all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a persistent bearish trend. This technical positioning aligns with the broader market environment, where the Sensex, despite recovering from an initial negative opening, remains 4.26% above its own 52-week low of 71,425.01. The Sensex’s current trading below its 50-day moving average, with the 50 DMA itself below the 200 DMA, reflects a cautious market backdrop, although mega-cap stocks are providing some support to the benchmark.
Financial Metrics and Fundamental Assessment
Link Pharma Chem Ltd’s financial profile continues to raise concerns. The company’s long-term operating profit growth has been negative, with a compound annual growth rate (CAGR) of -27.15% over the past five years. This decline in operating profitability has weighed heavily on investor sentiment and contributed to the stock’s weak performance.
The company’s ability to service its debt is limited, as indicated by a poor average EBIT to interest coverage ratio of 0.68. This suggests that earnings before interest and taxes are insufficient to comfortably cover interest expenses, raising questions about financial stability. Additionally, the average return on equity (ROE) stands at a modest 4.94%, reflecting low profitability relative to shareholders’ funds.
Over the last year, the stock has generated a negative return of 33.20%, significantly underperforming the Sensex, which posted a positive 1.07% return over the same period. The stock has also consistently underperformed the BSE500 index in each of the last three annual periods, highlighting a pattern of relative weakness.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Recent Operational Highlights
Despite the overall negative trend, Link Pharma Chem Ltd reported some positive results in the six months ending December 2025. Net sales grew by 28.40% to Rs.13.02 crores, while profit after tax (PAT) increased to Rs.0.09 crores. The company also recorded its highest quarterly PBDIT at Rs.0.69 crores during this period. These figures indicate pockets of improvement in revenue generation and profitability, albeit from a low base.
Valuation metrics present a mixed picture. The company’s return on capital employed (ROCE) is negative at -0.5%, yet it maintains an attractive valuation with an enterprise value to capital employed ratio of 0.9. This suggests that the stock is trading at a discount relative to its peers’ historical valuations. The price-to-earnings-to-growth (PEG) ratio stands at 0.6, reflecting the relationship between the stock’s price, earnings growth, and valuation.
Technical Indicators and Market Sentiment
Technical analysis continues to signal caution. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly timeframes. Bollinger Bands also indicate bearish momentum on these intervals. The Relative Strength Index (RSI) shows a bullish signal on the weekly chart but no clear indication on the monthly chart. Other technical tools such as the Know Sure Thing (KST) and Dow Theory assessments remain bearish or neutral, reinforcing the subdued market sentiment surrounding the stock.
Promoters remain the majority shareholders, maintaining control over the company’s strategic direction. However, the micro-cap status of Link Pharma Chem Ltd and its weak financial metrics have contributed to its current market standing.
Why settle for Link Pharma Chem Ltd? SwitchER evaluates this Commodity Chemicals micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Metrics
Link Pharma Chem Ltd’s current Mojo Score is 29.0, with a Mojo Grade of Strong Sell, upgraded from Sell on 13 Mar 2026. This rating reflects the company’s weak long-term fundamentals and ongoing underperformance. The stock’s 52-week high was Rs.42.80, indicating a decline of nearly 48% from that peak to the current low of Rs.22.31.
The company’s market capitalisation remains in the micro-cap category, which often entails higher volatility and risk. The stock’s day change of -11.01% and four-day cumulative loss of over 20% highlight the recent intensification of selling pressure.
Overall, Link Pharma Chem Ltd’s financial and technical indicators point to a challenging environment for the stock, with persistent downward pressure and limited signs of sustained recovery at present.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
